However, upon examination, the trial included only 11 osteosarcoma cases, of which only two cases showed strong immunohistochemistry expression of IGF1R, and no evaluation of IGF1R copy number was used to guide treatment. The gene discussed is IGF1R; the disease is osteosarcoma.